Those 600000 shares aren't worth much anymore NZ
There are a few other companies whos remuneration packages I will vote down, but I will not intervene in LCT.
As far as I see it, the study was solid. The results simply didn't come in as hoped. Ideally we could have had another 100 participants which might have yielded a different result, but the cost would have been prohibitive.
What else could have management done?
Ann: Results of LCT Parkinsons trial require further analysis, page-106
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
